Long-term safety outcomes in intracordal trafermin injection

Abstract

Although there are many reports on the usefulness of intracordal trafermin injections, there are few reports on its safety. In particular, the long-term safety after injection is unknown; therefore, we conducted a retrospective study of our medical records. There were 45 cases (27 males and 18 females), ranging in age from 11 to 88 years old, with a mean age of 53.5 years old. The cases included 21 cases of vocal fold paralysis, 16 cases of atrophy, 5 cases of sulcus, 2 cases of scar, and 1 case of hypoplasia. The average follow-up period and standard deviation of follow-up was 279.1 ± 205.3 (range: 0-693) days, and the average number and standard deviation of vocal fold examinations from post-injection to May 31, 2024, was 8.0 ± 5.1 (range: 0-20). Except for 2 patients who did not have any outpatient visits after the injection, 43 patients had no complications in the vocal folds during the follow-up period. The safety of this simple and highly effective intracordal trafermin injection may lead to future regulatory approval.